Relmada Therapeutics Inc’s recent filing unveils that its Chief Executive Officer TRAVERSA SERGIO acquired Company’s shares for reported $0.15 million on Sep 11 ’24. In the deal valued at $2.99 per share,51,407 shares were bought. As a result of this transaction, TRAVERSA SERGIO now holds 384,024 shares worth roughly $1.32 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, TRAVERSA SERGIO bought 55,579 shares, generating $150,619 in total proceeds. Upon buying the shares at $2.71, the Chief Executive Officer now owns 299,603 shares.
Before that, TRAVERSA SERGIO bought 33,014 shares. Relmada Therapeutics Inc shares valued at $90,788 were divested by the Chief Executive Officer at a price of $2.75 per share. As a result of the transaction, TRAVERSA SERGIO now holds 332,617 shares, worth roughly $1.14 million.
Jefferies upgraded its Relmada Therapeutics Inc [RLMD] rating to a Buy from a a Hold in a research note published on September 17, 2024; the price target was increased to $13 from $3.50. A number of analysts have revised their coverage, including Goldman’s analysts, who decreased its forecast for the stock in early June from “a Neutral” to “a Sell”. Truist also remained covering RLMD and has decreased its forecast on October 14, 2022 with a “Hold” recommendation from previously “Buy” rating. Guggenheim revised its rating on October 14, 2022. It rated RLMD as “a Neutral” which previously was an “a Buy”.
Price Performance Review of RLMD
On Tuesday, Relmada Therapeutics Inc [NASDAQ:RLMD] saw its stock jump 13.53% to $3.44. Over the last five days, the stock has gained 22.42%. Relmada Therapeutics Inc shares have fallen nearly -16.91% since the year began. Nevertheless, the stocks have risen 11.33% over the past one year. While a 52-week high of $7.22 was reached on 03/04/24, a 52-week low of $1.88 was recorded on 08/12/24. SMA at 50 days reached $3.23, while 200 days put it at $3.79.
Levels Of Support And Resistance For RLMD Stock
The 24-hour chart illustrates a support level at 3.17, which if violated will result in even more drops to 2.90. On the upside, there is a resistance level at 3.74. A further resistance level may holdings at 4.04. The Relative Strength Index (RSI) on the 14-day chart is 62.44, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.36, which suggests price will go down in the next trading period. Percent R suggests that price movement has been 30.00 at 30.00%. Stochastics %K at 54.17% indicates the stock is a holding.
How much short interest is there in Relmada Therapeutics Inc?
A steep rise in short interest was recorded in Relmada Therapeutics Inc stocks on 2024-08-30, dropping by -0.12 million shares to a total of 1.21 million shares. Yahoo Finance data shows the prior-month short interest on 2024-07-31 was 1.33 million shares. There was a decline of -10.31%, which implies that there is a negative sentiment for the stock.
